Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.
Abstract
BACKGROUND
In addition to the oncogenic human papillomavirus (HPV), several cofactors are needed in cervical carcinogenesis, but whether
the HPV covariates associated with incident (i) CIN1 are different from those of incident (ii) CIN2 and (iii) CIN3 needs further
assessment.
OBJECTIVES
To gain further insights into the true biological differences between CIN1, CIN2 and CIN3, we assessed HPV covariates associated
with incident CIN1, CIN2, and CIN3.
STUDY DESIGN AND METHODS
HPV covariates associated with progression to CIN1, CIN2 and CIN3 were analysed in the combined cohort of the NIS (n = 3187)
and LAMS study (n = 12,114), using competing-risks regression models (in panel data) for baseline HR-HPV-positive women (n
= 1105), who represent a sub-cohort of all 1865 women prospectively followed-up in these two studies.
RESULTS
Altogether, 90 (4.8%), 39 (2.1%) and 14 (1.4%) cases progressed to CIN1, CIN2, and CIN3, respectively. Among these baseline
HR-HPV-positive women, the risk profiles of incident CIN1, CIN2 and CIN3 were unique in that completely different HPV covariates
were associated with progression to CIN1, CIN2 and CIN3, irrespective which categories (non-progression, CIN1, CIN2, CIN3
or all) were used as competing-risks events in univariate and multivariate models.
CONCLUSIONS
These data confirm our previous analysis based on multinomial regression models implicating that distinct covariates of HR-HPV
are associated with progression to CIN1, CIN2 and CIN3. This emphasises true biological differences between the three grades
of CIN, which revisits the concept of combining CIN2 with CIN3 or with CIN1 in histological classification or used as a common
endpoint, e.g., in HPV vaccine trials.
Authors
Syrjänen K, Shabalova I, Sarian L, Naud P, Longatto-Filho A, Derchain S, Kozachenko V, Zakharchenko S, Roteli-Martins C, Nerovjna R, Kljukina L, Tatti S, Branovskaja M, Branca M, Grunjberga V, Erzen M, Juschenko A, Serpa Hammes L, Podistov J, Costa S, Syrjänen S, NIS Study Research Group, LAMS Study Research Group
Institution
Department of Oncology & Radiotherapy, Turku University Hospital, Turku, Finland. kari.syrjanen@tyks.fi
Source
European journal of gynaecological oncology 33:1 2012 pg 5-14MeSH
AdolescentAdult
Aged
Aged, 80 and over
Cervical Intraepithelial Neoplasia
Contraceptives, Oral
Disease Progression
Female
Humans
Middle Aged
Multivariate Analysis
Papillomavirus Infections
Regression Analysis
Risk Factors
Smoking
Uterine Cervical Neoplasms
Vaginal Smears
Young Adult
Pub Type(s)
Journal ArticleResearch Support, Non-U.S. Gov't
Language
eng
PubMed ID
22439398
Log In

